Johns Hopkins University
Baltimore, Maryland, 21287, United States
NCT Number: NCT01698489
Closer examination of granular lipid data in a large population offers numerous opportunities to generate new knowledge, ranging from studies examining concordance between commonly used lipid parameters to phenotypic characterization of rare or extreme disorders of lipid metabolism, opening possibilities to better personalize future treatment of abnormal blood lipids.
STUDY POPULATION:
The Very Large Database of Lipids (VLDL) includes adults and children who were clinically referred for a Vertical Auto Profile (VAP). Patient samples originated predominantly from outpatient primary care clinics in the U.S. (85%), along with specialty clinics and inpatient settings.
LIPID MEASUREMENTS:
The VAP test (VAP Diagnostics Lab, Birmingham, Alabama, USA) directly measures cholesterol concentrations of low density lipoprotein, very low density lipoprotein, intermediate density lipoprotein, high density lipoprotein, their subfractions, and lipoprotein(a). Triglycerides in the database are directly measured using the Abbott ARCHITECT C-8000 system (Abbott Park, Illinois, USA). Lipid distributions in the database closely match those from the population-representative National Health and Nutrition Examination Survey (NHANES).
STUDY PROCEDURES:
This database was investigator-initiated. Only de-identified data reach the investigational site. The master database is housed at The Johns Hopkins Hospital in Baltimore, Maryland, and maintained by Drs. Jones and Martin. The current database (2nd harvest) includes 5,051,467 patients whose laboratory samples were collected from October 1, 2015 and June 30, 2019. Only electronic data, and not blood samples, are sent to Hopkins. The academic investigators have unrestricted access to study data, take responsibility for the accuracy of analyses, and have authority over manuscript preparation and submission.
VARIABLES:
The variables currently in the VLDL database are testing date, age, sex, fasting/nonfasting, and components of the VAP test. From these primary variables, many additional variables were derived for inclusion in the master database. Other analytes measured by validated assays in subsets of the VLDL database include apolipoprotein B (apoB), apolipoprotein A1 (apoAI), high-sensitivity C-reactive protein (hsCRP), homocysteine, uric acid, insulin, hemoglobin A1c, 25-hydroxy vitamin D, cystatin C, lipoprotein-associated phosphatase (Lp-PLA2), thyroid stimulating hormone (TSH), free T3 and T4, pro-brain natriuretic peptide (pBNP), direct bilirubin, creatine phosphokinase (CPK), creatinine and other components of the comprehensive metabolic panel, magnesium, and phosphate.
This study is active but is not currently recruiting participants.
Notify MeAll sexes
Observational
Baltimore, Maryland, 21287, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Patients with age and lipid data are included in the master database. Eligibility criteria are specific to each individual study.
Time frame: 4 years
Low-density lipoprotein cholesterol levels measured in milligrams per deciliter.
Johns Hopkins University
Other
The Very Large Database of Lipids (VLDL): A Clinical Laboratory Big Data Project
Acronym: VLDL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06303570
Adiposis Dolorosa, Connective Tissue Diseases
Spokane, Washington, United States
View Trial DetailsNCT01911091
Body Weight, Disorder of Lipid Storage and Metabolism
Orlando, Florida, United States
View Trial DetailsNCT06832371
Arterial Occlusive Diseases, Arteriosclerosis
Lille, France
View Trial DetailsNCT04975594
Dyslipidemias, Lipid Metabolism Disorders
Leipzig, Saxony, Germany
View Trial Details